..Warrants granted in the year ended December 31, 2020 were valued using the Black Scholes Model..expected volatility ranging of 411.72% ..Series BB Preferred Stock.. calculated at a price of $1.20.. ..Global Stem Cells Group’s operations cover every aspect of the regenerative medicine industry. ..$11,600,000.. have a three (3) year maturity date ..Revenue from viable cell therapy and immune support related products along with physician training was $153,583 from August 19, 2021 to September 30, 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group. ..Other expense decreased by $6,460,049 for the three months ended September 30, 2021